Herpes zoster cost-effectiveness of therapy: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
m (Bot: Removing from Primary care)
 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
{{Herpes zoster}}
{{Herpes zoster}}
{{CMG}}; L. Katie Morrison, MD; '''Associate Editor(s)-In-Chief:''' {{CZ}}
{{CMG}}
 
 


Please help WikiDoc by adding more content here.  It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Overview==
A live [[vaccine]] for VZV exists, marketed as [[Zostavax]].<ref name="MMWR_57(05)">{{cite journal
| author = Harpaz R, Ortega-Sanchez IR, Seward JF
| title = Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)
| journal = MMWR Recomm Rep
| volume = 57
| issue = RR–5
| pages = 1–30; quiz CE2–4
| date = June 6, 2008
| pmid = 18528318
| doi =
| url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5705a1.htm
| accessdate = 2010-01-04
}}</ref> A systematic review by the [[Cochrane Library]] concluded that Zostavax can reduce the incidence of herpes zoster by almost 50%.<ref>{{cite journal |author=Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG |title=Vaccines for preventing herpes zoster in older adults |journal=Cochrane Database Syst Rev |volume=10 |issue= |pages=CD008858 |year=2012 |pmid=23076951 |doi=10.1002/14651858.CD008858.pub2 |editor1-last=Gagliardi |editor1-first=Anna MZ}}</ref> A 2007 study found that the zoster vaccine is likely to be cost-effective in the U.S., projecting an annual savings of $82 to $103 million in healthcare costs with cost-effectiveness ratios ranging from $16,229 to $27,609 per [[quality-adjusted life year]] gained.<ref>{{cite journal |journal=Vaccine |year=2007 |volume=25 |issue=49 |pages=8326–37 |title= Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults |author= Pellissier JM, Brisson M, Levin MJ |doi=10.1016/j.vaccine.2007.09.066 |pmid=17980938}}</ref> In October 2007 the vaccine was officially recommended in the U.S. for healthy adults aged 60 and over.<ref name="MMWR_57(05)"/><ref name=pmid17947396>{{cite journal |journal= Ann Intern Med |date=20 November 2007|volume=147 |issue=10 |pages=725–9 |title= Recommended adult immunization schedule: United States, October 2007 – September 2008 |author= Advisory Committee on Immunization Practices |pmid=17947396 |url=http://www.annals.org/cgi/content/full/147/10/725 |doi= 10.7326/0003-4819-147-10-200711200-00187 }}</ref>
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WS}}
{{WH}}
[[Category:Infectious skin diseases]]
[[Category:Infectious skin diseases]]
[[Category:Viral diseases]]
[[Category:Viral diseases]]
[[Category:Herpesviruses]]
[[Category:Herpesviruses]]
[[Category:Infectious disease]]
[[Category:Needs content]]
 
{{WS}}
{{WH}}

Latest revision as of 22:09, 29 July 2020

Herpes zoster Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Herpes zoster from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Herpes Zoster
Congenital Varicella Syndrome

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Herpes zoster cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Herpes zoster cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Herpes zoster cost-effectiveness of therapy

CDC on Herpes zoster cost-effectiveness of therapy

Herpes zoster cost-effectiveness of therapy in the news

Blogs on Herpes zoster cost-effectiveness of therapy

Directions to Hospitals Treating Herpes zoster

Risk calculators and risk factors for Herpes zoster cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.

Overview

A live vaccine for VZV exists, marketed as Zostavax.[1] A systematic review by the Cochrane Library concluded that Zostavax can reduce the incidence of herpes zoster by almost 50%.[2] A 2007 study found that the zoster vaccine is likely to be cost-effective in the U.S., projecting an annual savings of $82 to $103 million in healthcare costs with cost-effectiveness ratios ranging from $16,229 to $27,609 per quality-adjusted life year gained.[3] In October 2007 the vaccine was officially recommended in the U.S. for healthy adults aged 60 and over.[1][4]

References

  1. 1.0 1.1 Harpaz R, Ortega-Sanchez IR, Seward JF (June 6, 2008). "Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP)". MMWR Recomm Rep. 57 (RR–5): 1–30, quiz CE2–4. PMID 18528318. Retrieved 2010-01-04.
  2. Gagliardi AM, Gomes Silva BN, Torloni MR, Soares BG (2012). Gagliardi, Anna MZ, ed. "Vaccines for preventing herpes zoster in older adults". Cochrane Database Syst Rev. 10: CD008858. doi:10.1002/14651858.CD008858.pub2. PMID 23076951.
  3. Pellissier JM, Brisson M, Levin MJ (2007). "Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults". Vaccine. 25 (49): 8326–37. doi:10.1016/j.vaccine.2007.09.066. PMID 17980938.
  4. Advisory Committee on Immunization Practices (20 November 2007). "Recommended adult immunization schedule: United States, October 2007 – September 2008". Ann Intern Med. 147 (10): 725–9. doi:10.7326/0003-4819-147-10-200711200-00187. PMID 17947396.

Template:WS Template:WH